Company intelligence / Profile preview

EUREKA! Venture

Emeryville, California, United States

Ownership: Private
Employees: ~67
Development stage: Other

Overview

ARYA-3 clinical trial advanced to Phase II for GPC3-targeting ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced liver cancer; ARYA-2 Phase I ongoing for pediatric liver cancer with CIRM grant support.[1]

Therapeutic areas: Oncology
Modalities: T cell therapyARTEMIS T-cell therapy
Industry: Biotech

Partnerships

National Cancer Institute (NCI) for MSLN and GPC2 antibodies

Beyond the preview

Go deeper on EUREKA! Venture.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EUREKA! Venture.

Explore the full profile